Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 75.23 Billion KRW | 11.27% |
| 2022 | 68.83 Billion KRW | 22.24% |
| 2021 | 56.31 Billion KRW | -3.44% |
| 2020 | 58.32 Billion KRW | -8.42% |
| 2019 | 63.68 Billion KRW | 5.32% |
| 2018 | 60.46 Billion KRW | -2.44% |
| 2017 | 61.98 Billion KRW | 31.49% |
| 2016 | 47.13 Billion KRW | 11.49% |
| 2015 | 42.27 Billion KRW | 1.81% |
| 2014 | 41.52 Billion KRW | 2.01% |
| 2013 | 40.71 Billion KRW | 3.67% |
| 2012 | 39.26 Billion KRW | -16.06% |
| 2011 | 46.78 Billion KRW | -2.22% |
| 2010 | 47.84 Billion KRW | -6.7% |
| 2009 | 51.27 Billion KRW | -3.97% |
| 2008 | 53.39 Billion KRW | -3.49% |
| 2007 | 55.33 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 18.55 Billion KRW | 4.52% |
| 2024 Q3 | 19.45 Billion KRW | 4.85% |
| 2024 Q1 | 17.75 Billion KRW | -1.06% |
| 2023 Q3 | 18.99 Billion KRW | -15.68% |
| 2023 Q2 | 22.52 Billion KRW | 31.47% |
| 2023 Q1 | 17.13 Billion KRW | 3.96% |
| 2023 Q4 | 17.94 Billion KRW | -5.53% |
| 2023 FY | 76.59 Billion KRW | 11.27% |
| 2022 Q3 | 18.17 Billion KRW | 1.71% |
| 2022 FY | 68.83 Billion KRW | 22.24% |
| 2022 Q4 | 16.48 Billion KRW | -9.35% |
| 2022 Q2 | 17.87 Billion KRW | 9.64% |
| 2022 Q1 | 16.3 Billion KRW | 24.48% |
| 2021 Q2 | 15.55 Billion KRW | 30.26% |
| 2021 Q3 | 15.72 Billion KRW | 1.12% |
| 2021 Q1 | 11.93 Billion KRW | -19.62% |
| 2021 FY | 56.31 Billion KRW | -3.44% |
| 2021 Q4 | 13.09 Billion KRW | -16.71% |
| 2020 Q1 | 14.94 Billion KRW | -2.06% |
| 2020 Q4 | 14.85 Billion KRW | 11.23% |
| 2020 Q2 | 15.16 Billion KRW | 1.48% |
| 2020 Q3 | 13.35 Billion KRW | -11.96% |
| 2020 FY | 58.32 Billion KRW | -8.42% |
| 2019 Q3 | 16.17 Billion KRW | -3.01% |
| 2019 FY | 63.68 Billion KRW | 5.32% |
| 2019 Q2 | 16.67 Billion KRW | 7.02% |
| 2019 Q4 | 15.26 Billion KRW | -5.62% |
| 2019 Q1 | 15.57 Billion KRW | 22.36% |
| 2018 Q1 | 15.78 Billion KRW | -35.06% |
| 2018 Q2 | 16.51 Billion KRW | 4.61% |
| 2018 Q3 | 15.43 Billion KRW | -6.51% |
| 2018 FY | 60.46 Billion KRW | -2.44% |
| 2018 Q4 | 12.73 Billion KRW | -17.52% |
| 2017 FY | 61.98 Billion KRW | 31.49% |
| 2017 Q4 | 24.3 Billion KRW | 88.5% |
| 2017 Q3 | 12.89 Billion KRW | -1.81% |
| 2017 Q2 | 13.13 Billion KRW | 12.73% |
| 2017 Q1 | 11.64 Billion KRW | -3.04% |
| 2016 Q1 | 11.33 Billion KRW | 1.39% |
| 2016 Q2 | 12.82 Billion KRW | 13.12% |
| 2016 Q4 | 12.01 Billion KRW | 9.6% |
| 2016 Q3 | 10.96 Billion KRW | -14.5% |
| 2016 FY | 47.13 Billion KRW | 11.49% |
| 2015 Q1 | 10.44 Billion KRW | 2.62% |
| 2015 FY | 42.27 Billion KRW | 1.81% |
| 2015 Q4 | 11.18 Billion KRW | 16.46% |
| 2015 Q3 | 9.59 Billion KRW | -13.12% |
| 2015 Q2 | 11.04 Billion KRW | 5.74% |
| 2014 Q2 | 10.72 Billion KRW | 8.07% |
| 2014 Q1 | 9.92 Billion KRW | 1.77% |
| 2014 Q4 | 10.18 Billion KRW | -4.78% |
| 2014 FY | 41.52 Billion KRW | 2.01% |
| 2014 Q3 | 10.69 Billion KRW | -0.31% |
| 2013 Q1 | 9.45 Billion KRW | -0.24% |
| 2013 Q2 | 10.73 Billion KRW | 13.53% |
| 2013 Q3 | 10.77 Billion KRW | 0.39% |
| 2013 Q4 | 9.75 Billion KRW | -9.47% |
| 2013 FY | 40.71 Billion KRW | 3.67% |
| 2012 Q3 | 10.04 Billion KRW | 16.88% |
| 2012 FY | 39.26 Billion KRW | -16.06% |
| 2012 Q1 | 11.07 Billion KRW | -7.42% |
| 2012 Q2 | 8.59 Billion KRW | -22.39% |
| 2012 Q4 | 9.47 Billion KRW | -5.72% |
| 2011 FY | 46.78 Billion KRW | -2.22% |
| 2011 Q1 | 11.73 Billion KRW | 13.89% |
| 2011 Q2 | 11.74 Billion KRW | 0.07% |
| 2011 Q3 | 11.33 Billion KRW | -3.44% |
| 2011 Q4 | 11.96 Billion KRW | 5.55% |
| 2010 Q3 | 12.26 Billion KRW | -7.08% |
| 2010 Q1 | 12.06 Billion KRW | -7.07% |
| 2010 Q4 | 10.3 Billion KRW | -16.03% |
| 2010 FY | 47.84 Billion KRW | -6.7% |
| 2010 Q2 | 13.2 Billion KRW | 9.44% |
| 2009 FY | 51.27 Billion KRW | -3.97% |
| 2009 Q4 | 12.98 Billion KRW | -10.39% |
| 2009 Q3 | 14.48 Billion KRW | 12.45% |
| 2009 Q2 | 12.88 Billion KRW | 17.99% |
| 2009 Q1 | 10.91 Billion KRW | -11.5% |
| 2008 Q3 | 10.45 Billion KRW | -36.32% |
| 2008 Q4 | 12.33 Billion KRW | 18.04% |
| 2008 Q2 | 16.41 Billion KRW | 15.65% |
| 2008 Q1 | 14.19 Billion KRW | -5.12% |
| 2008 FY | 53.39 Billion KRW | -3.49% |
| 2007 Q2 | 15.15 Billion KRW | 15.32% |
| 2007 FY | 55.33 Billion KRW | 0.0% |
| 2007 Q3 | 12.08 Billion KRW | -20.23% |
| 2007 Q4 | 14.95 Billion KRW | 23.76% |
| 2007 Q1 | 13.13 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -61.785% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 79.336% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 62.17% |
| HANDOK Inc. | 151.36 Billion KRW | 50.294% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -11.92% |
| Yuhan Corporation | 564.5 Billion KRW | 86.672% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 76.65% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -216.831% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 90.999% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -0.265% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 62.185% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -85.089% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 20.396% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 46.585% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -61.785% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -116.726% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 2.057% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 724.61% |
| JW Holdings Corporation | 446.15 Billion KRW | 83.136% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 63.747% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 88.519% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.586% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 4.301% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -4.191% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 59.068% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -61.785% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 74.506% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 88.961% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.586% |
| Yuhan Corporation | 564.5 Billion KRW | 86.672% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 62.721% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -6.06% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 24.023% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.586% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 48.429% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 56.632% |
| CKD Bio Corp. | 5.01 Billion KRW | -1401.667% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 70.406% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 59.137% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 23.325% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 4.301% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 79.747% |
| Boryung Corporation | 333.26 Billion KRW | 77.424% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -50.339% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 62.185% |
| JW Lifescience Corporation | 51.32 Billion KRW | -46.591% |